Literature DB >> 19731977

Altered chemokine receptor expression in papillary thyroid cancer.

Hernán E González1, Andrea Leiva, Hugo Tobar, Karen Böhmwald, Grace Tapia, Javiera Torres, Lorena M Mosso, Susan M Bueno, Pablo Gonzalez, Alexis M Kalergis, Claudia A Riedel.   

Abstract

BACKGROUND: Papillary thyroid cancer (PTC), the most prevalent type of differentiated thyroid carcinoma, displays a strikingly high frequency of lymph node metastasis (LNM). Recent data suggest that chemokines can play an important role in promoting tumor progression and metastatic migration of tumor cells. Here we have evaluated whether PTC tissues express a different pattern of chemokine receptors and if the expression of these receptors correlates with LNM.
METHODS: We assessed by immunohistochemistry and flow cytometry the expression of the chemokine receptors CCR3, CCR7, and CXCR4 in tumor and nonmalignant thyroid tissues from patients suffering from PTC. Expression of these receptors in PTC was correlated with the clinical pathological condition of PTC.
RESULTS: Our data show a significant enhancement of CCR3 (2.5 times higher, p = 0.038) and CXCR4 (1.7 times higher, p = 0.02) expression in PTC tissues as determined by immunohistochemical staining, and of CCR3 (3.5 times higher, p < 0.002) in the plasma membrane as determined by flow cytometric analyses, compared to controls. In addition, while CCR3 (100%) and CXCR4 (90%) were present in both tumor and control thyroid tissues, expression of CCR7 was scarcely detected in PTC cells (5-10%) and not found in control cells. CXCR4 expression correlated with the classical variant of PTC (p < 0.035) and extranodal extension (p < 0.010) in patients with LNM.
CONCLUSIONS: Our data support the notion that CCR3, CCR7, and CXCR4 are increasingly expressed in tumor cells from PTC and that CXCR4 expression in PTC could be a potential marker for enhanced tumor aggressiveness.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19731977     DOI: 10.1089/thy.2008.0432

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  6 in total

1.  Different CXCR4 expression according to various histologic subtype of papillary thyroid carcinoma.

Authors:  Dong Yeob Shin; Kwang Joon Kim; Cheol Ryong Ku; Mi Kyung Lee; Soo Il Jee; Woong Youn Chung; Eun Jig Lee
Journal:  Endocr Pathol       Date:  2013-12       Impact factor: 3.943

2.  Cell surface nucleolin interacts with CXCR4 receptor via the 212 c-terminal portion.

Authors:  Hongxin Niu; Xiangshan Yang; Zhongfa Xu; Tong Du; Ruogu Wang
Journal:  Tumour Biol       Date:  2014-10-19

Review 3.  C-C Chemokine Receptor 7 in Cancer.

Authors:  Colin A Bill; Christopher M Allen; Charlotte M Vines
Journal:  Cells       Date:  2022-02-14       Impact factor: 6.600

4.  Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.

Authors:  Max Czajkowski; Daniel Kaemmerer; Jörg Sänger; Guido Sauter; Ralph M Wirtz; Stefan Schulz; Amelie Lupp
Journal:  BMC Cancer       Date:  2022-07-07       Impact factor: 4.638

5.  Cell surface nucleolin is crucial in the activation of the CXCL12/CXCR4 signaling pathway.

Authors:  Xiangshan Yang; Zhongfa Xu; Daotang Li; Shaomei Cheng; Kaixi Fan; Chengjun Li; Aiping Li; Jing Zhang; Man Feng
Journal:  Tumour Biol       Date:  2013-08-06

Review 6.  Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.

Authors:  Pablo A González; Leandro J Carreño; Pablo F Céspedes; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Clin Dev Immunol       Date:  2013-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.